Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma

Journal of Proteome Research

Volumn 13, Issue 2, 2014, Pages 844-854

  Slany, Astrid ^a   Haudek Prinz, Verena ^a   Meshcheryakova, Anastasia ^b   Bileck, Andrea ^a   Lamm, Wolfgang ^c   Zielinski, Christoph ^c   Gerner, Christopher ^a   Drach, Johannes ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

comparative proteome profiling; multiple myeloma; primary human cells; tumor stroma interactions

Indexed keywords

BONE MARROW CELLS; DISEASE PROGRESSION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; MULTIPLE MYELOMA;

EID: 84893841791     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr400881p     Document Type: Article

References (55)

1. Seidl, S.; Kaufmann, H.; Drach, J. New insights into the pathophysiology of multiple myeloma Lancet Oncol. 2003, 4 (9) 557-64
2. Kyle, R. A.; Rajkumar, S. V. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression Br. J. Hamaetol. 2007, 139 (5) 730-43
3. Bergsagel, P. L.; Kuehl, W. M. Molecular pathogenesis and a consequent classification of multiple myeloma J. Clin. Oncol. 2005, 23 (26) 6333-8
4. Landgren, O.; Kyle, R. A.; Pfeiffer, R. M.; Katzmann, J. A.; Caporaso, N. E.; Hayes, R. B.; Dispenzieri, A.; Kumar, S.; Clark, R. J.; Baris, D.; Hoover, R.; Rajkumar, S. V. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood 2009, 113 (22) 5412-7
5. Landgren, O.; Kyle, R. A.; Rajkumar, S. V. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention Clin. Cancer Res. 2011, 17 (6) 1243-52
6. Landgren, O. Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology Hematol. Am. Soc. Hematol. Educ. Prog. 2010, 2010, 295-302
7. Bissell, M. J.; Hines, W. C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression Nat. Med. 2011, 17 (3) 320-9
8. Zipori, D. The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell Cancer Microenviron. 2010, 3 (1) 15-28
9. Mitsiades, C. S.; Mitsiades, N. S.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions Eur. J. Cancer 2006, 42 (11) 1564-73
10. Corre, J.; Mahtouk, K.; Attal, M.; Gadelorge, M.; Huynh, A.; Fleury-Cappellesso, S.; Danho, C.; Laharrague, P.; Klein, B.; Reme, T.; Bourin, P. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma Leukemia 2007, 21 (5) 1079-88
11. Zdzisinska, B.; Walter-Croneck, A.; Kandefer-Szerszen, M. Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients Leuk. Res. 2008, 32 (11) 1763-9
12. Garayoa, M.; Garcia, J. L.; Santamaria, C.; Garcia-Gomez, A.; Blanco, J. F.; Pandiella, A.; Hernandez, J. M.; Sanchez-Guijo, F. M.; del Canizo, M. C.; Gutierrez, N. C.; San Miguel, J. F. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors Leukemia 2009, 23 (8) 1515-27
13. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144 (5) 646-74
14. Hideshima, T.; Mitsiades, C.; Tonon, G.; Richardson, P. G.; Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets Nat. Rev. Cancer 2007, 7 (8) 585-98
15. Degrassi, A.; Hilbert, D. M.; Rudikoff, S.; Anderson, A. O.; Potter, M.; Coon, H. G. In vitro culture of primary plasmacytomas requires stromal cell feeder layers Proc. Natl. Acad. Sci. U. S. A. 1993, 90 (5) 2060-4
16. Pagnucco, G.; Cardinale, G.; Gervasi, F. Targeting multiple myeloma cells and their bone marrow microenvironment Ann. N.Y. Acad. Sci. 2004, 1028, 390-9
17. Givant-Horwitz, V.; Davidson, B.; Reich, R. Laminin-induced signaling in tumor cells Cancer Lett. 2005, 223 (1) 1-10
18. Pierce, R. A.; Griffin, G. L.; Mudd, M. S.; Moxley, M. A.; Longmore, W. J.; Sanes, J. R.; Miner, J. H.; Senior, R. M. Expression of laminin alpha3, alpha4, and alpha5 chains by alveolar epithelial cells and fibroblasts Am. J. Respir. Cell Mol. Biol. 1998, 19 (2) 237-44
19. Patarroyo, M.; Tryggvason, K.; Virtanen, I. Laminin isoforms in tumor invasion, angiogenesis and metastasis Semin. Cancer Biol. 2002, 12 (3) 197-207
20. Dalton, W. S.; Hazlehurst, L.; Shain, K.; Landowski, T.; Alsina, M. Targeting the bone marrow microenvironment in hematologic malignancies Semin. Hematol. 2004, 41 (2 Suppl 4) 1-5
21. Hazlehurst, L. A.; Argilagos, R. F.; Emmons, M.; Boulware, D.; Beam, C. A.; Sullivan, D. M.; Dalton, W. S. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells Cancer Res. 2006, 66 (4) 2338-45
22. Vincent, T.; Mechti, N. Extracellular matrix in bone marrow can mediate drug resistance in myeloma Leuk. Lymphoma 2005, 46 (6) 803-11
23. Gundacker, N. C.; Haudek, V. J.; Wimmer, H.; Slany, A.; Griss, J.; Bochkov, V.; Zielinski, C.; Wagner, O.; Stockl, J.; Gerner, C. Cytoplasmic proteome and secretome profiles of differently stimulated human dendritic cells J. Proteome Res. 2009, 8 (6) 2799-811
24. Haudek-Prinz, V. J.; Klepeisz, P.; Slany, A.; Griss, J.; Meshcheryakova, A.; Paulitschke, V.; Mitulovic, G.; Stockl, J.; Gerner, C. Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cells J. Proteomics 2012, 10.1016/j.jprot.2012.07.012
25. Slany, A.; Haudek, V. J.; Zwickl, H.; Gundacker, N. C.; Grusch, M.; Weiss, T. S.; Seir, K.; Rodgarkia-Dara, C.; Hellerbrand, C.; Gerner, C. Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B J. Proteome Res. 2010, 9 (1) 6-21
26. Wimmer, H.; Gundacker, N. C.; Griss, J.; Haudek, V. J.; Stattner, S.; Mohr, T.; Zwickl, H.; Paulitschke, V.; Baron, D. M.; Trittner, W.; Kubicek, M.; Bayer, E.; Slany, A.; Gerner, C. Introducing the CPL/MUW proteome database: interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells Electrophoresis 2009, 30 (12) 2076-89
27. Kline, M.; Donovan, K.; Wellik, L.; Lust, C.; Jin, W.; Moon-Tasson, L.; Xiong, Y.; Witzig, T. E.; Kumar, S.; Rajkumar, S. V.; Lust, J. A. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression Leuk. Res 2007, 31 (5) 591-8
28. Cumova, J.; Potacova, A.; Zdrahal, Z.; Hajek, R. Proteomic analysis in multiple myeloma research Mol. Biotechnol. 2011, 47 (1) 83-93
29. Micallef, J.; Dharsee, M.; Chen, J.; Ackloo, S.; Evans, K.; Qiu, L.; Chang, H. Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma J. Hematol. Oncol. 2010, 3, 13
30. Mortz, E.; Krogh, T. N.; Vorum, H.; Gorg, A. Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis Proteomics 2001, 1 (11) 1359-63
31. Slany, A.; Haudek, V. J.; Gundacker, N. C.; Griss, J.; Mohr, T.; Wimmer, H.; Eisenbauer, M.; Elbling, L.; Gerner, C. Introducing a new parameter for quality control of proteome profiles: consideration of commonly expressed proteins Electrophoresis 2009, 30 (8) 1306-28
32. Nesvizhskii, A. I.; Keller, A.; Kolker, E.; Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry Anal. Chem. 2003, 75 (17) 4646-58
33. Griss, J.; Gerner, C. GPDE: a biological view on PRIDE J. Proteomics Bioinf. 2009, 2 (4) 167-74
34. Griss, J.; Haudek-Prinz, V.; Gerner, C. GPDE: A biological proteomic database for biomarker discovery and evaluation Proteomics 2011, 11 (5) 1000-1004
35. Ishihama, Y.; Oda, Y.; Tabata, T.; Sato, T.; Nagasu, T.; Rappsilber, J.; Mann, M. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein Mol. Cell Proteomics 2005, 4 (9) 1265-72
36. Gotzmann, J.; Gerner, C. A method to produce Ponceau replicas from blots: application for Western analysis Electrophoresis 2000, 21 (3) 523-5
37. Rothlein, R.; Mainolfi, E. A.; Kishimoto, T. K. Treatment of inflammation with anti-ICAM-1 Res. Immunol. 1993, 144 (9) 735-9 (discussion 754-62).
38. Gundacker, N.; Bayer, E.; Traxler, E.; Zwickl, H.; Kubicek, M.; Stockl, J.; Gerner, C. Knowledge-based proteome profiling: considering identified proteins to evaluate separation efficiency by 2-D PAGE Electrophoresis 2006, 27 (13) 2712-21
39. Ashburner, M.; Ball, C. A.; Blake, J. A.; Botstein, D.; Butler, H.; Cherry, J. M.; Davis, A. P.; Dolinski, K.; Dwight, S. S.; Eppig, J. T.; Harris, M. A.; Hill, D. P.; Issel-Tarver, L.; Kasarskis, A.; Lewis, S.; Matese, J. C.; Richardson, J. E.; Ringwald, M.; Rubin, G. M.; Sherlock, G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium Nat. Genet. 2000, 25 (1) 25-9
40. Lahsnig, C.; Mikula, M.; Petz, M.; Zulehner, G.; Schneller, D.; van Zijl, F.; Huber, H.; Csiszar, A.; Beug, H.; Mikulits, W. ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression Oncogene 2009, 28 (5) 638-50
41. Allen, M.; Louise Jones, J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer J. Pathol. 2011, 223 (2) 162-76
42. Yi, C. H.; Smith, D. J.; West, W. W.; Hollingsworth, M. A. Loss of fibulin-2 expression is associated with breast cancer progression Am. J. Pathol. 2007, 170 (5) 1535-45
43. Vora, S. R.; Guo, Y.; Stephens, D. N.; Salih, E.; Vu, E. D.; Kirsch, K. H.; Sonenshein, G. E.; Trackman, P. C. Characterization of recombinant lysyl oxidase propeptide Biochemistry 2010, 49 (13) 2962-72
44. Paulitschke, V.; Kunstfeld, R.; Mohr, T.; Slany, A.; Micksche, M.; Drach, J.; Zielinski, C.; Pehamberger, H.; Gerner, C. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells J. Proteome Res. 2009, 8 (5) 2501-10
45. Yagci, M.; Sucak, G. T.; Haznedar, R. Fibrinolytic activity in multiple myeloma Am. J. Hematol. 2003, 74 (4) 231-7
46. Neri, P.; Bahlis, N. J. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma Curr. Cancer Drug Targets 2012, 12 (7) 776-96
47. Gregoretti, M. G.; Gottardi, D.; Ghia, P.; Bergui, L.; Merico, F.; Marchisio, P. C.; Caligariscappio, F. Characterization of Bone-Marrow Stromal Cells from Multiple-Myeloma Leuk. Res. 1994, 18 (9) 675-682
48. Veevers-Lowe, J.; Ball, S. G.; Shuttleworth, A.; Kielty, C. M. Mesenchymal stem cell migration is regulated by fibronectin through alpha5beta1-integrin-mediated activation of PDGFR-beta and potentiation of growth factor signals J. Cell Sci. 2011, 124 (Pt 8) 1288-300
49. Paulsson, J.; Sjoblom, T.; Micke, P.; Ponten, F.; Landberg, G.; Heldin, C. H.; Bergh, J.; Brennan, D. J.; Jirstrom, K.; Ostman, A. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer Am. J. Pathol. 2009, 175 (1) 334-41
50. Nabeshima, K.; Iwasaki, H.; Koga, K.; Hojo, H.; Suzumiya, J.; Kikuchi, M. Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression Pathol. Int. 2006, 56 (7) 359-367
51. Koga, K.; Nabeshima, K.; Aoki, M.; Kawakami, T.; Hamasaki, M.; Toole, B. P.; Nakayama, J.; Iwasaki, H. Emmprin in epithelioid sarcoma: expression in tumor cell membrane and stimulation of MMP-2 production in tumor-associated fibroblasts Int. J. Cancer 2007, 120 (4) 761-8
52. Arendt, B. K.; Walters, D. K.; Wu, X.; Tschumper, R. C.; Huddleston, P. M.; Henderson, K. J.; Dispenzieri, A.; Jelinek, D. F. Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation Leukemia 2012, 26, 2286-96
53. Messaritou, G.; East, L.; Roghi, C.; Isacke, C. M.; Yarwood, H. Membrane type-1 matrix metalloproteinase activity is regulated by the endocytic collagen receptor Endo180 J. Cell Sci. 2009, 122 (Pt 22) 4042-8
54. Wienke, D.; Davies, G. C.; Johnson, D. A.; Sturge, J.; Lambros, M. B.; Savage, K.; Elsheikh, S. E.; Green, A. R.; Ellis, I. O.; Robertson, D.; Reis-Filho, J. S.; Isacke, C. M. The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo Cancer Res. 2007, 67 (21) 10230-40
55. Curino, A. C.; Engelholm, L. H.; Yamada, S. S.; Holmbeck, K.; Lund, L. R.; Molinolo, A. A.; Behrendt, N.; Nielsen, B. S.; Bugge, T. H. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy J. Cell Biol. 2005, 169 (6) 977-85